Literature DB >> 20843793

Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

Yusuke Higashi1, Kevin Holder, Patrice Delafontaine.   

Abstract

There is increasing evidence that thiazolidinediones (TZDs), antidiabetic compounds that are synthetic ligands for the peroxisome proliferator-activated receptor γ (PPARγ), have cardiovascular effects through as yet poorly defined mechanisms. We tested the effect of two TZD class drugs, rosiglitazone and pioglitazone, on human aortic smooth muscle cell (SMC) expression of insulin-like growth factor-1 receptor (IGF-1R). Both TZDs dose dependently up-regulated IGF-1R protein levels (rosiglitazone, 10 μmol/liter, 67% increase, n = 4, p < 0.01; pioglitazone, 10 μmol/liter, 41% increase, n = 4, p < 0.01) and increased IGF-1R signaling activity (36% increase in Akt phosphorylation). However, the endogenous PPARγ ligand, 15-deoxy-Δ(12,14)-prostaglandin J(2), dose dependently reduced IGF-1R (10 μmol/liter, 80% decrease, n = 4, p < 0.01), and overexpression of PPARγ using an adenovirus likewise reduced IGF-1R (50% decrease versus SMC infected with control adenovirus), suggesting a PPARγ-independent action of TZDs. All three PPARγ ligands (rosiglitazone, pioglitazone, and 15-deoxy-Δ(12,14)-prostaglandin J(2)), however, did not change IGF-1R mRNA levels, indicating that their effects were posttranscriptional. Use of bicistronic constructs revealed that TZD induction of IGF-1R translation occurred via internal ribosomal entry. To examine the potential physiological relevance of TZD up-regulation of IGF-1R, we determined the effect of rosiglitazone on oxidized LDL (oxLDL)-induced apoptosis. 20 μmol/liter of rosiglitazone reduced oxidized LDL-induced apoptosis by 40% and neutralizing antibody to IGF-1R (αIR3) counteracted this rescue, suggesting the rosiglitazone survival effect was, at least in part, mediated by IGF-1R. In conclusion, TZDs markedly up-regulate SMC IGF-1R expression and signaling, likely via a PPARγ-independent mechanism. This novel action of TZDs may play an important role in their cardiovascular effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843793      PMCID: PMC2978564          DOI: 10.1074/jbc.M110.137661

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Searching for IRES.

Authors:  Stephen D Baird; Marcel Turcotte; Robert G Korneluk; Martin Holcik
Journal:  RNA       Date:  2006-09-06       Impact factor: 4.942

2.  Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.

Authors:  Guobin He; You Me Sung; John Digiovanni; Susan M Fischer
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

3.  Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells.

Authors:  Zheng Meng; Nateka L Jackson; Hyoungsoo Choi; Peter H King; Peter D Emanuel; Scott W Blume
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

4.  Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids.

Authors:  Anannya Banga; Resat Unal; Preeti Tripathi; Irina Pokrovskaya; Randall J Owens; Philip A Kern; Gouri Ranganathan
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-12-16       Impact factor: 4.310

Review 5.  Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity.

Authors:  Grant D Barish
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

6.  IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice.

Authors:  Sergiy Sukhanov; Yusuke Higashi; Shaw-Yung Shai; Charlotte Vaughn; Jessica Mohler; Yangxin Li; Yao-Hua Song; Jane Titterington; Patrick Delafontaine
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

7.  Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

Authors:  Eva M Lonn; Hertzel C Gerstein; Patrick Sheridan; Sandra Smith; Rafael Diaz; Viswanathan Mohan; Jackie Bosch; Salim Yusuf; Gilles R Dagenais
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

8.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

9.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu
Journal:  JAMA       Date:  2008-03-31       Impact factor: 56.272

10.  Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.

Authors:  Kathleen A Martin; Bethany L Merenick; Min Ding; Kristina M Fetalvero; Eva M Rzucidlo; Courtney D Kozul; David J Brown; Helen Y Chiu; Maureen Shyu; Bethany L Drapeau; Robert J Wagner; Richard J Powell
Journal:  J Biol Chem       Date:  2007-09-30       Impact factor: 5.157

View more
  7 in total

1.  Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

Authors:  Brian R Hoffmann; Mohamed F El-Mansy; Daniel S Sem; Andrew S Greene
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

Review 2.  Aging, atherosclerosis, and IGF-1.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-04-05       Impact factor: 6.053

Review 3.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

Review 4.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

5.  Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.

Authors:  Vladimir Kus; Pavel Flachs; Ondrej Kuda; Kristina Bardova; Petra Janovska; Michaela Svobodova; Zuzana Macek Jilkova; Martin Rossmeisl; Rui Wang-Sattler; Zhonghao Yu; Thomas Illig; Jan Kopecky
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

6.  PPARγ induces growth inhibition and apoptosis through upregulation of insulin-like growth factor-binding protein-3 in gastric cancer cells.

Authors:  S Y Kim; M S Kim; M K Lee; J S Kim; H K Yi; S Y Nam; D Y Lee; P H Hwang
Journal:  Braz J Med Biol Res       Date:  2015-01-13       Impact factor: 2.590

7.  Association of hepatocellular carcinoma with thiazolidinediones use: A population-based case-control study.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.